• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022

    11/22/22 6:00:55 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MESO alert in real time by email

    Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L

    These long-term survival outcomes are a cornerstone of the BLA resubmission to FDA for approval of remestemcel-L in the treatment of children with SR-aGVHD

    NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended September 30, 2022 and provided an update on upcoming milestones.

    "The substantial and durable long-term survival over four years we have reported today in children with SR-aGVHD treated with remestemcel-L in our Phase 3 trial underscore the many lives that could potentially be saved by making this therapy available as soon as possible to children with the most common life-threatening complication after bone marrow transplantation" said Dr. Silviu Itescu, Chief Executive of Mesoblast.

    "These new long-term survival data reaffirm the potential significance of remestemcel-L as a life-saving therapy for children with SR-aGVHD and are a cornerstone of the company's BLA resubmission to the FDA for approval of remestemcel-L in the treatment of children with SR-aGVHD. The lack of any approved treatments for children under 12 means that there is an urgent need for a therapy that improves the dismal survival outcomes in children. We are at a pivotal juncture, we believe we have appropriately addressed issues raised by FDA in the complete response, and we are well funded in preparation for a potential first product approval and launch by mid-year."

    FINANCIAL HIGHLIGHTS

    • Cash: Cash reserves as at September 30th were US$85.5 million. Up to an additional US$40.0 million may be drawn from existing financing facilities subject to achieving certain milestones, with current discussions to extend the period for the drawdown option.
    • Net cash usage for operating activities in the quarter was US$14.3 million; this represented a 22% reduction (US$3.9 million) on the comparative quarter in FY2022, and a 47% reduction (US$12.5 million) on the comparative quarter in FY2021.
    • Revenue from royalties on sales of TEMCELL® HS Inj.1 sold in Japan by our licensee for the quarter were US$1.4 million. For the 12-month period ended September 30, 2022 royalties were US$7.7 million, and on a constant currency basis2 US$9.0 million, a 9% increase on the comparative period.
    • Expenditure for R&D, Manufacturing and Management & Administration inclusive of non-cash items, were US$17.5 million, a decrease of 23% (US$5.2 million) for the quarter ended September 30, 2022 on the comparative quarter.

    OPERATIONAL HIGHLIGHTS AND NEAR-TERM MILESTONES

    Remestemcel-L

    Biologics License Application (BLA) resubmission to the US Food and Drug Administration (FDA) for the treatment of children with steroid-refractory graft versus host disease (SR-aGVHD)

    • Survival outcomes have not improved over the past two decades for children or adults with the most severe forms of SR-aGVHD.3-6 The lack of any approved treatments for children under 12 means that there is an urgent need for a therapy that improves the dismal survival outcomes in children.
    • In light of the unmet need, remestemcel-L has been granted Fast Track Designation and BLA Priority Review from the FDA.
    • A major milestone in the Company's complete response to the FDA was the submission at the end of the last quarter of substantial new information on clinical and potency assay items to the Investigational New Drug (IND) file for remestemcel-L in the treatment of children with SR-aGVHD, as guided by FDA.
    • Mesoblast has optimized a potency assay that was in place at the time of the Phase 3 trial and which demonstrates a relationship between the product's activity in-vitro and its effects on survival in the Phase 3 trial.
    • Additionally, Mesoblast has now generated data from the expanded access program (EAP 275) of 241 children which confirm the ability of the in-vitro potency assay to measure product activity relevant to survival outcomes.
    • Today Mesoblast provided new results from a four-year observational survival study performed by the Center for International Blood and Marrow Transplant Research (CIBMTR) on 51 evaluable patients with SR-aGVHD who were enrolled in Mesoblast's phase 3 clinical trial of remestemcel-L.
    • Overall survival in the remestemcel-L cohort was 63% at 1 year, 51% at 2 years, and 49% at 4 years, while across four recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only FDA-approved agent for adults survival rates of 40-49% at 1 year and 25%-38% at 2 years were seen. 7-10
    • The new long-term survival data provide assurance that the short-term day 28 responses and early survival through 180 days in the 54-patient Phase 3 trial in children with SR-aGVHD previously presented to FDA in the original BLA submission are unlikely to have arisen by chance and are a cornerstone of the BLA resubmission.
    • Mesoblast is working towards a potential US approval for remestemcel-L and first product launch in H1 CY2023.
    • Additional indications for which remestemcel-L is being developed include acute respiratory distress syndrome and inflammatory bowel disease.

    Rexlemestrocel-L

    Chronic low back pain associated with degenerative disc disease:

    • Working towards FDA clearance by year end 2022 to commence the second Phase 3 trial for potential marketing approval in chronic lower back pain due to degenerative disc disease.
    • Mesoblast gained alignment with the FDA on key metrics for the Phase 3 study in patients with CLBP.
    • The primary endpoint for the study will be reduction in pain at 12 months, in line with FDA discussions and feedback.

    Chronic heart failure with reduced ejection fraction (HFrEF) in NYHA class II/III patients through to end-stage III/IV patients with a left ventricular assist device (LVAD):

    • Recent data from Phase 3 trial of 565 patients with HFrEF showed a single intervention with rexlemestrocel-L improves left ventricular ejection fraction (LVEF) at 12 months, preceding long-term reduction in major adverse cardiovascular events (MACE).
    • LVEF improvement at 12 months may be an appropriate early surrogate endpoint for long term reduction in MACE.
    • Plan to meet with FDA next quarter under existing regenerative medicine advanced therapy (RMAT) designation to discuss common mechanism of action in HFrEF including those with LVADs, and potential pathway to marketing approval.

    FINANCIAL RESULTS FOR THE PERIOD ENDED SEPTEMBER 30, 2022 (FIRST QUARTER FY2023)

    • Cash reserves as at September 30th were US$85.5 million. Up to an additional US$40.0 million may be drawn from existing financing facilities subject to achieving certain milestones, with current discussions to extend the period for the drawdown option.
    • Net cash usage for operating activities in the quarter was US$14.3 million; this represented a 22% reduction (US$3.9 million) on the comparative quarter in FY2022, and a 47% reduction (US$12.5 million) on the comparative quarter in FY2021.
    • Revenue from royalties on sales of TEMCELL® HS Inj.1 sold in Japan by our licensee for the quarter were US$1.4 million and US$1.8 million on a constant currency basis. For the 12-month period ended September 30, 2022 royalties were US$7.7 million, and on a constant currency basis2 US$9.0 million, a 9% increase on the comparative period.

      In the comparative quarter, there was one-off milestone revenue of US$1.2 million from Takeda for Japan approval of Alofisel® (darvadstrocel) for perianal fistulas.
    • Research & Development expenses reduced by US$3.6 million (38%), down to US$5.7 million for the first quarter FY2023 compared to US$9.3 million for the first quarter FY2022 as clinical trial activities for our COVID-19 ARDS, CLBP and CHF product candidates reduced given clinical trial recruitment and data analysis is now complete.
    • Manufacturing expenses reduced by US$2.7 million (35%), down to US$4.8 million for the first quarter FY2023 compared to US$7.5 million for the first quarter FY2022. During the quarter we continued pre-launch manufacturing activities and product testing for remestemcel-L to support the potential commercial launch for SR-aGVHD.

      We expect to recognize the US$28.0 million balance of remestemcel-L pre-launch inventory, and the balance of any further production completed at that time, on our balance sheet if we receive FDA approval.
    • Management and Administration expenses increased by US$1.0 million (17%), up to US$6.9 million for the first quarter FY2023 compared to US$5.9 million for the first quarter FY2022 primarily due to an increase in non-cash share-based payments and insurance costs.
    • Remeasurement of Contingent Consideration gains increased to US$4.5 million in the first quarter FY2023 compared to a gain of US$0.3 million for the first quarter FY2022 reflecting a reduction in future third party payments.
    • Fair value movement of warrants: recognized a loss of US$0.4 million in the first quarter FY2023 compared to Nil in the first quarter FY2022.
    • Finance Costs for borrowing arrangements with our lenders, Oaktree and NovaQuest, were US$4.5 million (actual cash interest paid US$1.2 million) for the first quarter FY2023, compared to US$3.7 million (actual cash interest paid US$1.2 million) for the first quarter FY2022.
    • Loss after tax for the first quarter FY2023 was US$16.9 million compared to US$22.6 million for the first quarter FY2022. The net loss attributable to ordinary shareholders was 2.43 US cents per share for the first quarter FY2023, compared with 3.49 US cents per share for the first quarter FY2022.

    Conference Call

    There will be a webcast today, beginning at 8.30am AEDT (Wednesday, November 23); 4.30pm ET (Tuesday, November 22). It can be accessed via: https://webcast.openbriefing.com/9143/

    The archived webcast will be available on the Investor page of the Company's website: www.mesoblast.com

    About Mesoblast

    Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

    Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

    Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast's licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

    Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

    References / Footnotes

    1. TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd.
    2. TEMCELL sales by our Licensee are recorded in Japanese Yen before being translated into USD for the purposes of calculating the royalty paid to Mesoblast. Results have been adjusted for the movement of the USD to Japanese Yen exchange rate from 1USD:110.2Yen for the 12 months ended September 30, 2021 to 1USD:129.2Yen for the 12 months ended September 30, 2022.
    3. Niederwieser D, Baldomero H, Szer J. (2016) Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey.
    4. HRSA Transplant Activity Report, CIBMTR, 2019
    5. Westin, J., Saliba, RM., Lima, M. (2011) Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology.
    6. Axt L, Naumann A, Toennies J (2019) Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation.
    7. Rashidi A et al. Outcomes and predictors of response in steroid-refractory acute graft-versus-host disease: single-center results from a cohort of 203 patients. Biol Blood Bone Marrow Transplant 2019; 25(11):2297-2302.
    8. MacMillan ML et al. Pediatric acute GVHD: clinical phenotype and response to upfront steroids. Bone Marrow Transplant 2020; 55(1): 165-171

    9. Zeiser R et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med 2020;382:1800-10.

    10. Jagasia M et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749.

    Forward-Looking Statements

    This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals (including BLA resubmission), manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

    Release authorized by the Chief Executive.

    For more information, please contact:



     
    Corporate Communications / InvestorsMedia
    Paul HughesBlueDot Media
    T: +61 3 9639 6036Steve Dabkowski
    E: [email protected]T: +61 419 880 486
     E: [email protected]
      
     Rubenstein
     Tali Mackay
     E: [email protected]



    Consolidated Income Statement



      Three Months Ended

    September 30,
     
    (in U.S. dollars, in thousands, except per share amount) 2022  2021 
    Revenue  1,503   3,594 
    Research & development  (5,744)  (9,328)
    Manufacturing commercialization  (4,866)  (7,537)
    Management and administration  (6,898)  (5,878)
    Fair value remeasurement of contingent consideration  4,468   280 
    Fair value remeasurement of warrant liability  (401)  — 
    Other operating income and expenses  (504)  (178)
    Finance costs  (4,497)  (3,660)
    Loss before income tax  (16,939)  (22,707)
    Income tax benefit/(expense)  55   62 
    Loss attributable to the owners of Mesoblast Limited  (16,884)  (22,645)
             
    Losses per share from continuing operations attributableto the ordinary equity holders of the Group: Cents  Cents 
    Basic - losses per share  (2.43)  (3.49)
    Diluted - losses per share  (2.43)  (3.49)



    Consolidated Statement of Comprehensive Income



      Three Months Ended

    September 30,
     
    (in U.S. dollars, in thousands) 2022  2021 
    Loss for the period  (16,884)  (22,645)
    Other comprehensive (loss)/income        
    Items that may be reclassified to profit and loss        
    Exchange differences on translation of foreign operations  (159)  (349)
    Items that will not be reclassified to profit and loss        
    Financial assets at fair value through other comprehensive income  86   154 
    Other comprehensive (loss)/income for the period, net of tax  (73)  (195)
    Total comprehensive losses attributable to theowners of Mesoblast Limited  (16,957)  (22,840)



    Consolidated Balance Sheet



      As of

    September 30,
      As of

    June 30,
     
    (in U.S. dollars, in thousands) 2022  2022 
    Assets        
    Current Assets        
    Cash & cash equivalents  85,502   60,447 
    Trade & other receivables  3,863   4,403 
    Prepayments  3,595   4,987 
    Total Current Assets  92,960   69,837 
             
    Non-Current Assets        
    Property, plant and equipment  1,786   2,045 
    Right-of-use assets  7,730   7,920 
    Financial assets at fair value through other comprehensive income  1,843   1,758 
    Other non-current assets  1,902   1,930 
    Intangible assets  578,275   578,652 
    Total Non-Current Assets  591,536   592,305 
    Total Assets  684,496   662,142 
             
    Liabilities        
    Current Liabilities        
    Trade and other payables  17,663   23,079 
    Provisions  19,455   17,906 
    Borrowings  5,489   5,017 
    Lease liabilities  3,609   3,186 
    Warrant liability  2,586   2,185 
    Total Current Liabilities  48,802   51,373 
             
    Non-Current Liabilities        
    Provisions  9,853   12,523 
    Borrowings  94,186   91,617 
    Lease liabilities  6,348   7,085 
    Deferred consideration  2,500   2,500 
    Total Non-Current Liabilities  112,887   113,725 
    Total Liabilities  161,689   165,098 
    Net Assets  522,807   497,044 
             
    Equity        
    Issued Capital  1,207,734   1,165,309 
    Reserves  70,873   70,651 
    (Accumulated losses)/retained earnings  (755,800)  (738,916)
    Total Equity  522,807   497,044 



    Consolidated Statement of Cash Flows



      Three Months Ended

    September 30,
     
    (in U.S. dollars, in thousands) 2022  2021 
    Cash flows from operating activities        
    Commercialization revenue received  2,219   1,995 
    Government grants and tax incentives received  —   24 
    Payments to suppliers and employees (inclusive of goods and services tax)  (16,566)  (20,222)
    Interest received  60   4 
    Net cash (outflows) in operating activities  (14,287)  (18,199)
             
    Cash flows from investing activities        
    Investment in fixed assets  (153)  (99)
    Payments for licenses  (50)  — 
    Net cash (outflows) in investing activities  (203)  (99)
             
    Cash flows from financing activities        
    Payment of transaction costs from borrowings  (151)  (100)
    Interest and other costs of finance paid  (1,381)  (1,407)
    Proceeds from issue of shares  45,065   147 
    Payments for share issue costs  (2,565)  (104)
    Payments for lease liabilities  (670)  (686)
    Net cash inflows/(outflows) by financing activities  40,298   (2,150)
             
    Net increase/(decrease) in cash and cash equivalents  25,808   (20,448)
    Cash and cash equivalents at beginning of period  60,447   136,881 
    FX (loss) on the translation of foreign bank accounts  (753)  (477)
    Cash and cash equivalents at end of period  85,502   115,956 



    Primary Logo

    Get the next $MESO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MESO

    DatePrice TargetRatingAnalyst
    12/23/2024Buy → Hold
    Jefferies
    9/24/2024$12.00Hold → Buy
    Maxim Group
    8/29/2024Hold → Buy
    Jefferies
    7/23/2024$4.00 → $11.00Neutral → Overweight
    Piper Sandler
    8/31/2023Hold → Buy
    Jefferies
    8/7/2023Buy → Hold
    Maxim Group
    8/4/2023$7.00 → $2.00Overweight → Neutral
    Piper Sandler
    8/4/2023Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity means that the FDA will not approve another mesenchymal stromal or stem cell (MSC) products for this indication during the 7-year period from the approval of Ryoncil®. Separately, Mesoblast has biologic exclusivity prev

      5/14/25 10:57:06 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. "We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication," said Dr. Silviu Itescu, CEO of Mesoblast. "With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory di

      4/29/25 8:53:27 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited. Ms. Cobley is currently a director of Commonwealth Bank of Australia, is a member of Chief Executive Women, a member of the Macquarie

      4/28/25 7:44:18 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mesoblast downgraded by Jefferies

      Jefferies downgraded Mesoblast from Buy to Hold

      12/23/24 7:24:07 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast upgraded by Maxim Group with a new price target

      Maxim Group upgraded Mesoblast from Hold to Buy and set a new price target of $12.00

      9/24/24 8:11:34 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast upgraded by Jefferies

      Jefferies upgraded Mesoblast from Hold to Buy

      8/29/24 7:56:03 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Leadership Updates

    Live Leadership Updates

    See more
    • Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. "We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication," said Dr. Silviu Itescu, CEO of Mesoblast. "With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory di

      4/29/25 8:53:27 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited. Ms. Cobley is currently a director of Commonwealth Bank of Australia, is a member of Chief Executive Women, a member of the Macquarie

      4/28/25 7:44:18 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dr. Gregory George MD PhD Joins Mesoblast Board

      NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast's largest shareholder, to its Board of Directors. Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization. Mesoblast Founder and Chief

      2/23/25 6:33:52 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    SEC Filings

    See more
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      5/14/25 8:46:57 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      4/29/25 9:39:45 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      4/29/25 7:13:53 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      12/16/24 12:08:07 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      10/9/24 3:42:14 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      7/11/24 7:38:31 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Financials

    Live finance-specific insights

    See more
    • Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

      NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. Mesoblast Chief Executive Silviu Itescu said: "During the past year we have built significant momentum in our interactions with the United States Food and Drug Administration (FDA) across each of our Phase 3 products. I am very pleased that our Biologics License Application (BLA) resubmission for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD)

      8/28/24 7:27:43 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

      NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: "We were very busy operationally during the last quarter and continued to have positive engagement with the United States Food and Drug Administration (FDA) across our lead programs. We have strengthened our balance sheet while maintaining overall spending constraint in line with our corporate objectives. For our product Ryoncil® (remestemcel-L) for life-threatening steroid-ref

      2/28/24 5:57:09 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

      NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: "We had anticipated that remestemcel-L would have been approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a condition with a high mortality where there are no approved therapies for children under 12 years old. During the six-month B

      8/30/23 7:07:02 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care